Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer - Top-Institutions - MDSpire

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

  • By

  • Hailin Zhu

  • Wang Yi

  • Yujie Wu

  • Rong Li

  • Boxuan Zhou

  • June 16, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunotherapy
    • Tumor Microenvironment

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Immunology
    • Cancer Research

  • #3

    Center for Cancer Immune Therapy, Herlev Hospital
    Center for Cancer Immune Therapy, Herlev Hospital

    Herlev, Denmark

    Key Differentiators

    • Oncology
    • Cancer Immunotherapy

  • #4

    Herlev and Gentofte Hospital
    Herlev and Gentofte Hospital

    Herlev, Denmark

    Key Differentiators

    • Oncology
    • Clinical Trials

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Cancer Research

Original Source(s)

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

  • by Hailin Zhu, Wang Yi, Yujie Wu, Rong Li, Boxuan Zhou

  • June 16, 2026

Related Content

Group painting therapy for children and adolescents with bone tumors: a quasi-experimental trial evaluating anxiety, depression, post-traumatic growth, and health-related quality of life

Late recurrence and histological progression of a cervical intradural extramedullary solitary fibrous tumor after gross total resection: a case report

Futile Radiotherapy for Patients With Cancer Near the End of Life